Periplocymarin is primarily studied for its potential anticancer properties. It has shown cytotoxic effects against various cancer cell lines, particularly in lung and liver cancers, by inducing apoptosis and inhibiting cell proliferation. Research also suggests it may interfere with tumor growth by targeting specific signaling pathways involved in cancer progression. Additionally, periplocymarin exhibits cardiotonic activity, similar to other cardiac glycosides, meaning it can enhance cardiac contraction and is being explored for heart-related conditions. However, due to its narrow therapeutic window, its use is limited and mainly confined to preclinical research. It is also investigated for its anti-inflammatory and immunomodulatory effects, contributing to its potential in multifaceted therapeutic applications.